I
onotropic glutamate receptors (iGluRs) are ligand-gated ion channels that mediate most excitatory neurotransmission in the central nervous system (1) . iGluRs are implicated in nearly all aspects of nervous system development and function, and their dysfunction is associated with devastating chronic neurodegenerative conditions, such as Alzheimer's and Parkinson's diseases; psychiatric disorders, such as schizophrenia and depression; and acute disorders, such as brain trauma and stroke (1) (2) (3) . The iGluR family includes three major subtypes: AMPA, kainate (KA), and N-methyl-D-aspartate (NMDA) receptors, which have diverse kinetic and pharmacological properties and play disparate roles in cognition but share common structural features (1) .
iGluRs function as assemblies of four subunits. Whereas the majority of iGluRs in the nervous system are heterotetramers composed of at least two types of subunits, AMPA and select KA subunits can form functional homotetramers. Each iGluR subunit has a modular design (4) and includes an extracellular amino-terminal domain (ATD) that controls subunit assembly, receptor trafficking, channel gating, agonist potency, and allosteric modulation; a clamshell-shaped ligandbinding domain (LBD or S1S2) composed of two stretches of polypeptide, S1 and S2, and responsible for agonist and antagonist recognition; a transmembrane domain (TMD) that forms a cationconducting channel and contributes to iGluR tetrameric stability; and a cytoplasmic C-terminal domain involved in synaptic localization, trafficking, mobility, and receptor regulation (1) . Currently, structural information on iGluRs is limited to high-resolution crystal structures of genetically excised, water-soluble ATDs and LBDs and 3.6 to 4.0 Å resolution structures of an intact AMPA receptor in the antagonist-bound closed state (5) and NMDA receptors in the allosterically inhibited agonist-bound closed state (6, 7) .
iGluRs function by opening their ion channel in response to binding of agonist glutamate (Glu) (1) . This process of activation gating is accompanied by the typically slower process of desensitization, which leads to closure of the ion channel and causes a reduction of iGluR-mediated currents in the continuous presence of Glu. Desensitization represents a versatile mechanism for shaping synaptic transmission (8) , and controlling it could be an effective way of regulating synaptic integration, modulating circuit function, and altering iGluR activity in pathological conditions (1, 9) . Here, we used a combination of biochemical and biophysical approaches to study iGluR gating. We focused on AMPA subtype rat GluA2 receptors, for which a modified construct, GluA2 cryst , had previously yielded the structure in the closed antagonistbound state (5). We used a construct, GluA2*, that is similar to GluA2 cryst but has several mutations reversed back toward the wild-type GluA2 background (see supplementary materials).
For functional characterization, we expressed GluA2* in human embryonic kidney (HEK) 293 cells and used patch clamp with fast solution exchange to record GluA2*-mediated currents. As is typical for AMPA subtype iGluRs at near-physiological membrane potentials, Glu application elicited an inward current that quickly decayed in the continuous presence of Glu as a result of desensitization (Fig.  1A) . Desensitization in GluA2* receptors had a similar rate and extent as in wild-type receptors ( fig. S1 , A and D) and was blocked by the positive allosteric modulator cyclothiazide (CTZ) (10) .
AMPA receptors can also be activated by partial agonists, which elicit smaller maximal whole-cell currents than the full agonist Glu but have similar single-channel conductance (11) (12) (13) . In our studies, we used a partial agonist, (S)-5-nitrowillardiine (NOW). In crystal structures of isolated LBD, NOW demonstrated the ability to keep the LBD clamshell completely closed (13) , just like full agonists. NOW elicited currents with~four times smaller maximal amplitude than Glu and had similar potency for GluA2* and wild-type GluA2 receptors ( fig. S1 , B and C). The rates of desensitization and, to a greater extent, recovery from it for NOW were apparently slower than those for Glu ( fig. S1 , D to G). Kinetic modeling of the effects of full and partial agonists on AMPA receptors (14) We purified GluA2* and crystallized it in the presence of NOW. The best crystals belonged to the C222 1 space group and diffracted to 4.8 Å resolution (table S1). We solved the structure (GluA2 NOW ) by molecular replacement, using the high-resolution structure of the isolated ATD dimer [Protein Data Bank (PDB) identification code (ID) 3H5V] (15) and the ion channel domain from GluA2 cryst (PDB ID 3KG2) (5) as search models. The NOW-bound structure of the isolated LBD (PDB ID 3RTW) (13) did not work as a molecular replacement search model for LBD, suggesting that the LBD conformation is different in the context of GluA2 NOW . We solved the structure by separately using the D1 and D2 lobes of LBD as molecular replacement search models. The conformation of LBD in the GluA2 NOW structure most closely resembles the 6-cyano-7-nitroquinoxaline-2,3-dione-bound conformation of the isolated LBD (PDB ID 3B7D) (16) , and their superposition yields a root mean square deviation (RMSD) of 0.31 Å. Phases were improved by multidomain noncrystallographic symmetry averaging, solvent flattening, and histogram matching. The electron density maps were of sufficient clarity to build the majority of linkers connecting the LBD to the ion channel and the ATD to the LBD ( fig. S3 ). The resulting model was refined to good crystallographic statistics and stereochemistry (R work /R free = 0.228/0.262, table S1).
The GluA2 NOW structure ( Fig. 1C) is shaped like the letter Y and has a domain arrangement similar to the antagonist ZK 200775 (ZK)-bound closedstate GluA2 cryst structure (5) . For better comparison with GluA2 NOW , we cocrystallized GluA2* with ZK (table S1). The resulting structure (GluA2 ZK ) closely resembles the original GluA2 cryst structure (superposition of individual domains of GluA2 ZK and GluA2 cryst yields RMSD of 0.3 to 1 Å).
Grossly, GluA2 NOW and GluA2 ZK have similar architectures ( Fig. 2A) . The conformations of ATD are very similar ( fig. S4A ). The ion channel of GluA2 NOW adopts a closed-pore conformation that is also similar to GluA2 ZK (figs. S4, B and C, and S5). Nevertheless, small differences in the cross-pore dimensions between two pairs of diagonal subunits A/C and B/D ( fig. S4 , D to G) suggest deeper expansion of the twofold rotational symmetry of extracellular domains into the extracellular half of the GluA2 NOW ion channel. The strongest difference in domain conformation was observed for the LBD: Each clamshell is~11°more closed in GluA2 NOW compared with GluA2 ZK (Fig. 2B) . The closure of individual clamshells results in wider and shorter conformations of the back-toback LBD dimers in GluA2 NOW (Fig. 2, C and D) .
The altered conformation of LBD dimers in GluA2 NOW results in increased tension in linkers connecting LBD to ATD and TMD. Because ATD and the ion channel maintain their closed-statelike conformations, the additional tension forces pull ATD dimers down, tilting them~1.2°away from the overall twofold axis of symmetry ( Fig. 2A) . Thẽ 2.4°splaying of the ATD dimers away from each other occurs around a hinge point at the ATD dimerdimer interface. This interface maintains nearly identical conformations in GluA2 NOW and GluA2 ZK , strongly supporting a critical role of ATD in iGluR tetramerization (1) . Simultaneously, the tension forces pull the ion channel up by making the whole structure~2 Å shorter and push the two LBD dimers toward each other. As a result, the interface between the two LBD dimers in GluA2 NOW becomes tighter and covers a surface area three times larger than that in GluA2 ZK ( fig. S4, H and  I) . Accordingly, the GluA2 NOW structure becomes 2 Å narrower at the level of the LBD. We tested the functional importance of agonistinduced tightening of the interface between two LBD dimers predicted by the GluA2 NOW structure in experiments with GluA2-I664C (Ile 664 →Cys 664 ) receptors activated by Glu. I664 residues are located in the middle of the dimer-dimer interface; the Ca's are 13.5 Å apart in GluA2 ZK and 11.3 Å apart in GluA2 NOW ( fig. S6A ). Cross-linking of I664C has been shown in experiments with purified receptors (5) . We compared the rates of GluA2-I664C receptor recovery from desensitization in reducing and nonreducing conditions. In nonreducing conditions, the recovery was incomplete ( fig. S6, B to D) , apparently because of slow peak current reduction. The reduction was faster with longer exposures to Glu, accompanied by a decrease in the steady-state current amplitude without substantial changes in the fast rate of desensitization, and completely reversed by dithiothreitol (DTT) ( fig. S6, E and F) . The majority of receptors quickly become nonconducting in the presence of agonist; thus, slow inactivation of GluA2-I664C receptors under nonreducing conditions is consistent with agonist-induced tightening of LBD dimer-dimer interface.
Compared with GluA2 ZK , the LBD clamshells in GluA2 NOW are~11°more closed (Fig. 2B) , presenting structural evidence of clamshell motion in the context of the intact, multidomain iGluR, consistent with studies of isolated LBDs (17) . The conformational change is smaller than in agonist-or partial agonist-bound structures of isolated LBD, where clamshells are up to~14°more closed than in GluA2 NOW ( fig. S7 ). Despite different extents of clamshell closure between the isolated LBD and GluA2 NOW , the orientation of the NOW molecule in the binding pocket is similar (fig. S8) . However, increased distances between atoms of NOW and the binding pocket residues (table S2) suggest weakened interactions. Perhaps the most unexpected feature of the GluA2 NOW structure is the conformation of the LBD dimer interface. Although the GluA2 NOW structure was crystallized at conditions apparently favoring desensitization (Fig. 1B) , the D1-D1 interface appears nearly intact rather than ruptured (18) . Indeed, the difference in distance between upper lobes D1 in GluA2 NOW and GluA2 ZK does not exceed 1 Å, whereas the distance between lower lobes D2 is~6 Å larger in GluA2 NOW (Fig. 2, C and D) .
To probe the LBD dimer-interface conformation at conditions favoring different gating states in solution, we substituted individual residues at this interface with cysteines (Fig. 3, A and B) and purified wild-type and cysteine-substituted GluA2* receptors in their tetrameric forms ( fig. S9) . Cysteine crosslinking was tested in the presence or absence of reducing agent (2 mM DTT) and in the presence of different ligands. The GluA2 NOW and GluA2 ZK structures predicted position-specific differences in cross-interface distances between substituted cysteines (Fig. 3C) , but nearly all of them were capable of forming cross-links in nonreducing conditions favoring all gating states: closed, open, and desensitized (Fig. 3D) . We obtained similar results for the wild-type and K493C full-length GluA2 receptors ( fig. S10 ). Such high reactivity of cysteines at the dimer interface indicates that LBD is highly dynamic (13, (19) (20) (21) (22) (23) (24) (25) (26) (27) and that its conformation fluctuates during gating. Because the cross-dimer disulfide bonds are unstable and reversible (20) , they cannot abolish these fluctuations (Fig. 3D ), but they can favor certain gating states.
To study the effect of LBD interface cross-linking on iGluR gating, we recorded Glu-activated currents from HEK 293 cells expressing wild-type or cysteine-substituted receptors (Fig. 4A and fig. S11 ). To separate effects on receptor activation and desensitization, we measured two parameters. The first parameter gives an estimate for the effect of crosslink on AMPA receptor activation (Fig. 4B) . No difference in activation between reducing and nonreducing conditions was observed for wild-type and K493C receptors. Cross-linking of cysteines in the lower D1-D1 interface (P494C and S497C; P, Pro; S, Ser) had a positive effect on activation. In a reducing environment, cysteine substitution of P494 almost entirely abolished iGluR function, whereas cross-linking recovered small currents, consistent with the very low probability of disulfide bond formation (Fig. 3D) . The S497C receptors demonstrated robust Glu-activated currents that had larger amplitudes under cross-linking conditions. Overall, strengthening of the D1-D1 interface seemed to promote channel ability to open, which was most obvious when cysteine substitutions themselves inhibited this ability. In contrast, cross-linking of cysteines substituted in the D2 lobe produced negative effects on iGluR activation that were stronger for positions located closer to the ion channel. Hence, the LBD D2 lobes interlocking appears to prevent their separation, which is necessary for channel opening.
The second parameter reflects apparent changes in AMPA receptor desensitization, particularly its inhibition (Fig. 4C) . No strong inhibition of desensitization was observed for wild type, K493C, or any receptors with cysteine substitutions in D2. Some of these mutant receptors had rates and extents of desensitization that were somewhat different from those of wild type (table S3) , but those effects were due to mutations themselves and did not depend on the redox condition. Moreover, it is possible that the D2 cysteine cross-links can promote desensitization by locking receptors in the nonconducting state, unable to activate (Fig. 4B) . Only P494C and S497C substitutions in the lower D1-D1 interface showed strongly reduced desensitization (Fig. 4C) . Whereas for P494C, inhibition of desensitization was apparently independent of redox condition, it was greatly enhanced by cysteine cross-linking in S497C receptors. The inhibition of desensitization observed in P494C and S497C receptors is reminiscent of the effect of the L483Y (L, Leu; Y, Tyr) mutation (28) and of CTZ binding (10, 29) , both of which take place at the D1-D1 interface.
On the basis of our mutational, structural, and functional experiments in combination with previous work, we present two possible gating models (fig. S12) ; both assume that LBDs are highly mobile (Fig. 3) ; agonist binding causes LBD clamshell closure (17) ; and channel opening occurs when LBD clamshells adopt their maximally closed conformation (22, 23, (30) (31) (32) , represented by agonistbound structures of isolated LBD (13, 17) with the D1-D1 interface intact ( fig. S7 ). The first model represents a traditional view (18) where the final desensitized state has the D1-D1 interface modified ( fig. S12A ). In this model, the GluA2 NOW structure represents the agonist-bound closed state, which is predicted to be a transient state with negligible occupancy (Fig. 1B and fig. S2F ) insufficient to produce protein crystals. Nevertheless, such a scenario is plausible if only a limited range of conformations of the protein is accessible in the solubilized receptor or the crystal lattice contacts substantially affect protein conformation.
The second model ( fig. S12B ) assumes two-step desensitization with GluA2 NOW representing a deep desensitized state. This model is consistent with the predictions of kinetic modeling that, at high NOW concentrations, the majority of receptors accumulate in the deep desensitized state (D 2 4 in fig. S2 ). It also predicts that the same tension forces, applied from ATD and the ion channel through the connecting linkers that open LBD clamshells during deactivation, help transition the receptor from the deep desensitized state back to the desensitized state. Therefore, the second model explains why mutations that change the rate of deactivation often produce similar effects on the rate of recovery from desensitization (14, 33, 34) . Independent of gating model, the entry into desensitization is associated with modification of the D1-D1 interface ( fig. S12) (18, 20, (35) (36) (37) . One possible modification is represented by structures of the S729C and G725C cross-linked isolated LBDs (18) where the D1-D1 interface is ruptured. However, K493C cross-linking does not affect desensitization (Fig. 4C ) and argues against these structures representing the desensitized state of the intact receptor. Alternatively, the D1-D1 interface modification might be a rotation of the D1 lobes relative to each other that does not change the distance between K493 lysines but introduces relative displacement of pairs of other residues at the D1-D1 interface. Correspondingly, mutations like L483Y (28) or S497C (Fig. 4C and fig. S11 ) or positive allosteric modulators like CTZ (10, 29) would block desensitization by imposing constraints on the D1-D1 interface rearrangement.
